Hagerty Q4 2025 slides: 91% net income surge, strategic shift ahead

Hagerty reported 2025 net income of $149M, up 91% YoY and ~35% above initial guidance ($102–$110M); revenue was $1,456M (+17%) and adjusted EBITDA $237M (+46%). Q4 net income was $29M (+238% YoY) and Q4 adjusted EBITDA $57M (+97%). The company will transition to a Markel fronting arrangement effective Jan 1, 2026—retaining 100% of premium and risk, paying ~2% fronting fees—and expects one-time transition costs of ~ $145M that drive 2026 guidance to a projected net loss of $41–$51M, written premium of $1,373–$1,385M (+15–16%), total revenue of $1,280–$1,300M (‑11–12% due to accounting changes), and adjusted EBITDA of $236–$247M.

Analysis

The market will likely treat this as an accounting story more than an underwriting one: headline losses tied to structural reporting changes will create near-term volatility and headline-driven selling, while underlying cash EBITDA and loss ratios (which investors will have to reconstruct) remain the true signal for 2027+. Expect a compression in the next 1–3 months as quant funds and retail sellers de-risk on GAAP volatility, then a slower, fundamentals-driven re-rating over 12–24 months if retention and unit economics hold.

The partner that ceded premium/control faces asymmetric reputational and P/L effects: reduced fee income and lower direct exposure to upside could depress its headline profitability metrics even as its risk profile becomes cleaner. That sets up a relative-value opportunity where the specialist that internalized risk reaps long-term operating leverage while the fronting provider shows earnings erosion — useful for pair trades and sector rotation into active underwriters with direct distribution.

Second-order supply effects: as the specialist assumes more run-off/reserve and growth capital, expect incremental demand for reinsurance and bank capital solutions, pressuring retrocession pricing and creating buys for capital providers to the specialty-insurer space. Finally, strategic distribution partnerships with large incumbents materially de-risk customer acquisition; if these scale, they shorten cash-payback horizons and materially increase optionality for M&A or accretive capital raises over the next 3–5 years.

Key Decisions for Investors

• Long HGTY equity on a >15% post-announcement gap-down (entry: scale in over 2 tranches). Timeframe 12–24 months. Rationale: buy the separation between accounting headline and cash underwriting; target 40–60% upside if retention and loss trends persist. Stop: 30% below cost basis.
• Pair trade — Long HGTY / Short MKL (dollar-neutral). Timeframe 6–18 months. Rationale: isolate re-rating of an active specialty underwriter versus a fronting/fee-earning insurer that will show near-term margin pressure. Size to 1–2% notional of book; unwind if relative performance flips >20% vs entry.
• Options hedge — Buy HGTY 9–12 month LEAPS call (~1–2x exposure) and sell nearer-dated calls (calendar covered spread) funded by short-term call premiums. Timeframe 9–12 months. Rationale: convex exposure to a multi-quarter re-rate while monetizing near-term vega risk. Risk: total premium paid capped to position size.
• Short MKL via put-spread (3–6 month) if MKL fails to hold its 50-day moving average on the next earnings cycle. Timeframe 3–6 months. Rationale: hedge against fee-income erosion and investor rotation out of fronting models; defined-risk downside with favorable roll-down if sentiment worsens.